Swiss- Israeli based company, fuses the know how of specialists in the pahrmacology and delivery fields with the aim to bring to the market novel drugs based on cannabinoid molecules as stand alone, and synergistic combinations with proper drug delivery technologies
Over 30 years of experience in the pharmaceutical world. Also engaged in medical technologies, e.g. maintaining a distribution network for high-end ICU products in Central Europe. He recognizes the potential of combining highly specialized experts with the current trends, e.g. such as drug delivery for medicinal Cannabis.
Cor-Act Advanced Technologies, developing a life supporting system, for patients dying from chronic heart failure). Cor-Act will shortly launch the first fully implantable, Cardiac Assist Device with no blood contact. Our solution is designed as a cost- effective technology to solve the growing gap between of patients waiting for a transplant / mechanical support and the actual expensive available therapies. The Cor-Act’s Cardiac Assist Device system incorporates a miniaturized implantable pump connected to silicone elements which are pressing the myocardium.
CytoReason is a big-data analytics company specializing in immunotherapy using its proprietary Cell-Centered Model. The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy datasets. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions that extend beyond the data provided by the customer and can be translated to valuable IP. CytoReason’s technology has yielded 2 pending patents, 7 scientific collaborations and 12 peer reviewed publications
Our technology integrates different genomic and proteomic measurements with clinical data and predicts cellular immunological pathways.
The proprietary machine-learning engine enhances its performance with each new dataset introduced, leveraging hundreds of published and unpublished immunotherapy trials. Its prior knowledge allows for ever-improving accuracy, translating high-resolution measurements to specific immune-cellular interactions. The system generates immune interaction networks that extend beyond the data provided by the customer.
CytoReason is generating valuable IP and Know-How for biotech and pharmaceutical companies, universities and research institutions throughout their basic research, drug development, and clinical trials.
Investment and Licensing (In/Out) Opportunity 1: Name
Experienced Vice President Of Business Development with a demonstrated history of working in the pharmaceuticals industry. Skilled in Medical Devices, Biotechnology, Fundraising, Biomedical Engineering, and Start-ups. Strong sales professional
Drooms AG is a leading European provider of secure cloud solutions. This software specialist facilitates highly secure access to confidential documents as well as the ability to safely exchange them with third parties beyond company firewalls. Confidential business processes, such as financing and licensing projects or Board Communication are handled securely, transparently and efficiently with Drooms. Headquartered in Frankfurt, Germany´s banking hub, Drooms is also expanding its global market presence and now has offices in Munich, London, Paris, Amsterdam, Zug, Madrid, Milan and Vienna. The company is well positioned to facilitate large-scale local and multi-jurisdictional transactions. Their professional expertise, top-tier reputation and innovative processes have laid the groundwork for a growing reputation in this market space. Selected References include Astellas, Hormosan, HRA Pharma, Novartis, NovImmune SA and Siemens.
Gynotech is a developer of SMAT solutions for uro-gynecology conditions such as vaginal prolapse and urinary incontinence.
Gynotech has developed the first smart, dynamic pessary that automatically adjust its size in response to the changing intr-abdominal pressures and thus provides a much better prevention of prolapse and urinary leakages.
Chairman & CEO (D.Sc. in biochemistry and pharmacology) - Meir served for 20 years as CEO of Israeli and Canadian hi-tech companies, including CEO of two technological incubators. Earlier, he was a senior executive at ICL (Israel Chemical Ltd.) Group.
Musli Thyropeutics is a clinical stage pharmaceutical company addressing high-grade cancers. The company's patented fix-dose combination is based on recent scientific findings. Musli is targeting Glioblastoma Multiforme and Brain Metastases as-well-as Lung cancer and other aggressive high-grade cancers. Musli is preparing for Phase 2/3 clinical trials starting in 2018. Our innovative adjunct approach to current standard of care is expected to facilitate quick penetration to some of the largest markets in oncology, composing a multi-billion opportunity.
Our fight starts by diagnosing bacterial resistance to antibiotics in record time, using microfluidics.
Our test will help doctors determine the most appropriate antibiotic treatment for their patients and provide same-day results, which will reduce the spread of resistant bacteria and significantly lower the burden on healthcare costs.
This revolutionary scientific development is supported by a Proof of Concept from the lab of Prof. Levenberg, Dean of the Technion Biomedical Engineering Faculty.
Diane Abensur is a Franco-Israeli entrepreneur and the CEO & co-founder of Nanosynex. She established the company in 2017 after graduating from the Technion Institute of Technology International M.B.A (Haifa, Israel). She graduated from E.D.H.E.C Business School (Lille, France) and obtained her Master Degree in Business Management. In between, she worked as a junior analyst in consulting and M&A on healthcare deals in Paris and New York.
Nanna Lüneborg is a Principal at Novo Ventures, a leading global life science investor, which participated in the IPO of Inventiva in February 2017. Novo Ventures is part of Novo A/S, the holding and investment company of the Novo Nordisk foundation. Prior to joining Novo A/S, she was part of the life science investment team at Apposite Capital, a London-based venture capital firm specialising in healthcare. In 2012, she joined Novo A/S, where she has been part of both the seed and venture investment teams. She has previous board experience from a range of biotech companies spanning start-up to late stage development, most recently from the board of ObsEva, which completed an IPO on NASDAQ in January 2017. She currently serves on the boards of Orphazyme and Epsilon-3 Bio, in addition to Inventiva.
Nanna holds a BA from University of Oxford, a PhD in Neuroscience from University College London as a Wellcome Trust Scholar, and an MBA from University of Cambridge, where she was a Sainsbury Scholar.
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Obvislim Ltd. is an Israeli Bio-medical startup developing technology that will allow the obese to eat almost whatever they want. The majority of obesity treatments limit the amount/sorts of food consumed by obese patients. This is wrong on a fundamental level, mainly because eating is so much fun. Our Team including physicians and engineers currently is in the POC level and we are searching for seed funding. Our vision is to free obese patients to enjoy food exactly as the non-obese do
Launched in Jan-2016, Paragate Medical is an Israeli innovative startup, aiming to revolutionize the heart failure epidemic management by introducing the first implantable medical device that actively and continuously prevents fluid overload in congestive heart failure patients. The device absorbs systemic extracellular fluid and drains it to the urinary system in a safe and controlled manner.
With its encouraging pre-clinical results and strong IP coverage, the company is currently looking to complete series A to support European based operation towards FIM trials.
Paragate's IPU is a minimally invasive, fully implantable device that continuously and actively drains excess systemic extracellular fluid, maintaining fluid overloaded heart failure patients in normal volumes and reducing the need for repeated hospitalizations for acute treatments.
CEO and Co-founder of Paragate Medical. Over 11 years’ experience in cardiovascular devices field in R&D engineering and management positions, from which 7 with Enopace Biomedical, pioneering the conceptualization and development of intravascular neurostimulation device. Holds B.Sc. in BME from the Technion, resulting in a spinoff startup (Pneumedicare) and an M.Sc. in BME from the Technion-IIT, awarding him with ISHR young investigator award for the research in cardiac resynchronization therapy.